Agalsidase Alpha ( DrugBank: Agalsidase alpha )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 6 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
Showing 1 to 6 of 6 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04281537 (ClinicalTrials.gov) | March 1, 2020 | 7/2/2020 | A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy. A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry D ... | A Multi-country Time and Motion Study to Describe the Experience of Clinicians, Patients and Their Caregivers During the Treatment of Fabry Disease With Enzyme Replacement Therapy With Agalsidase Alfa and Agalsidase Beta A Multi-country Time and Motion Study to Describe the Experience of Clinicians, Patients and Their C ... | Fabry Disease | Drug: Agalsidase Beta;Drug: Agalsidase Alpha | Amicus Therapeutics | NULL | Completed | 18 Years | N/A | All | 76 | United States;Brazil;Japan;Taiwan;Turkey | |
| 2 | NCT02956954 (ClinicalTrials.gov) | March 25, 2017 | 3/11/2016 | Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease | Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®) Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of ... | Anderson-Fabry Disease | Drug: Enzyme replacement therapy (Agalsidase alpha (Replagal®));Procedure: Magnetic Resonance Imaging Drug: Enzyme replacement therapy (Agalsidase alpha(Replagal®));Procedure: Magnetic Resonance Imaging ... | University Hospital, Rouen | NULL | Unknown status | 18 Years | N/A | All | 25 | N/A | France |
| 3 | EUCTR2007-005543-22-SI (EUCTR) | 18/03/2011 | 24/02/2011 | An investigation of 3 dosages of Replagal in adult patients with Fabry disease | A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regimens of Replagal Enzyme ReplacementTherapy in Adult Patients with Fabry Disease A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regim ... | Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive name: Replagal Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive nam ... | Shire Human Genetic Therapies, Inc. (Shire HGT) | NULL | Not Recruiting | Female: yes Male: yes | 43 | United States;Czech Republic;Slovenia;Paraguay;Finland;Australia;United Kingdom | |||
| 4 | EUCTR2007-005543-22-FI (EUCTR) | 18/05/2010 | 23/03/2010 | An investigation of 3 dosages of Replagal in adult patients with Fabry disease | A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regimens of Replagal Enzyme ReplacementTherapy in Adult Patients with Fabry Disease A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regim ... | Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive name: Replagal Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive nam ... | Shire Human Genetic Therapies, Inc. (Shire HGT) | NULL | Not Recruiting | Female: yes Male: yes | 43 | Phase 3;Phase 4 | United States;Czech Republic;Slovenia;Paraguay;Finland;Australia;United Kingdom | ||
| 5 | EUCTR2007-005543-22-GB (EUCTR) | 06/05/2010 | 17/08/2009 | An investigation of 3 dosages of Replagal in adult patients with Fabry disease | A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regi ... | Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Fabry Disease MedDRA version: 14.0;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive name: Replagal Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive nam ... | Shire Human Genetic Therapies, Inc. (Shire HGT) | NULL | Not Recruiting | Female: yes Male: yes | 43 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): yes Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | United States;Czech Republic;Slovenia;Paraguay;Finland;Australia;United Kingdom | ||
| 6 | EUCTR2007-005543-22-CZ (EUCTR) | 19/06/2008 | 02/01/2008 | An investigation of 3 dosages of Replagal in adult patients with Fabry disease | A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regimens of Replagal Enzyme ReplacementTherapy in Adult Patients with Fabry Disease A Multi-center, Open-Label, Randomized Study Evaluating the Safety andEfficacy of Three Dosing Regim ... | Fabry Disease MedDRA version: 14.1;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] Fabry Disease MedDRA version: 14.1;Level: PT;Classification code 10016016;Term: Fabry's disease;Syst ... | Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive name: Replagal Trade Name: Replagal Product Name: Replagal INN or Proposed INN: agalsidase alpha Other descriptive nam ... | Shire Human Genetic Therapies, Inc. (Shire HGT) | NULL | Not Recruiting | Female: yes Male: yes | 43 | United States;Czech Republic;Slovenia;Paraguay;Finland;Australia;United Kingdom |